文献速递银屑病与炎症性皮肤病

乌司奴单抗治疗6至12岁以下中重度斑块状银屑病患儿的开放标签CADMUS Jr研究

Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study.
PubMed 文献 · Br J Dermatol · 2020-05-10

CADMUS Jr是一项III期开放标签单臂多中心研究,评估乌司奴单抗治疗6至12岁以下中重度斑块状银屑病患者的疗效与安全性。44例患者接受按体重给药,第12周时77%达到PGA 0/1,84%达到PASI 75,64%达到PASI 90;未发现新的安全性问题。

要点

  • 乌司奴单抗治疗6至12岁以下中重度斑块状银屑病患儿有效。
  • 第12周PGA 0/1应答率77%,PASI 75应答率84%,PASI 90应答率64%。
  • 安全性与其他年龄组一致,未发现新的安全性问题。

核心结论

  • 乌司奴单抗可有效治疗6至12岁以下儿童中重度斑块状银屑病,且未发现新的安全性问题。

主要发现

  • 第12周时77%的患者达到PGA 0/1,84%达到PASI 75,64%达到PASI 90。
  • 抗药抗体发生率为10%(n=4),血清IL-17A/F和IL-22平均浓度在第12周和第52周显著降低。
  • 77%(34例)患者发生至少一次不良事件,7%(3例)发生严重不良事件。

临床怎么用

  • 对于6至12岁以下中重度斑块状银屑病患儿,乌司奴单抗按体重给药可作为治疗选择。

局限性

  • 本研究为开放标签单臂设计,样本量较小(44例),缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited options are available for treatment of paediatric psoriasis. OBJECTIVES: To evaluate the efficacy and safety of ustekinumab in paediatric patients with psoriasis (≥ 6 to < 12 years of age). METHODS: CADMUS Jr, a phase III, open-label, single-arm, multicentre study, evaluated ustekinumab in paediatric patients with moderate-to-severe plaque psoriasis. Patients received weight-based dosing of ustekinumab (< 60 kg: 0·75 mg kg-1 ; ≥ 60 to ≤ 100 kg: 45 mg; > 100 kg: 90 mg) administered by subcutaneous injection at weeks 0 and 4, then every 12 weeks through week 40. Study endpoints (all at week 12) included the proportions of patients achieving a Physician's Global Assessment score of cleared/minimal (PGA 0/1) and ≥ 75%/90% improvement in Psoriasis Area and Severity Index (PASI 75/90), and change in Children's Dermatology Life Quality Index (CDLQI). Serum ustekinumab concentrations, antidrug antibodies and cytokine levels were measured through week 52. Safety was evaluated through week 56. RESULTS: In total, 44 patients (median age 9·5 years) received at least one dose of ustekinumab. Three patients discontinued the study agent through week 40. At week 12, 77% of patients achieved PGA 0/1, 84% achieved PASI 75 and 64% achieved PASI 90 response. The mean change in CDLQI was -6·3. Trough serum ustekinumab concentrations reached steady state at weeks 28-52. The incidence of antidrug antibodies was 10% (n = 4). Mean serum concentrations of interleukin-17A/F and interleukin-22 were significantly reduced at weeks 12 and 52. Overall, 34 patients (77%) had at least one adverse event and three (7%) had a serious adverse event. CONCLUSIONS: Ustekinumab effectively treated moderate-to-severe psoriasis in paediatric patients, and no new safety concerns were identified. What is already known about this topic? Ustekinumab is approved for use in adolescents (≥ 12 to < 18 years of age) and adults (≥ 18 years) with moderate-to-severe psoriasis. What does this study add? Ustekinumab effectively treats moderate-to-severe psoriasis in paediatric patients (≥ 6 to < 12 years of age), with no new safety concerns. Linked Comment: Reich. Br J Dermatol 2020; 183:606-607.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Philipp S, Menter A, Nikkels AF, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020. PMID: 32173852. doi:10.1111/bjd.19018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。